Evidence map›Paper›PMID 41419741›Full record

ArticleNature communications2025

Pre-marking chromatin with H3K4 methylation is required for accurate zygotic genome activation and development.

Meghana S Oak, Marco Stock, Ana Janeva, Matthias Mezes, Antony M Hynes-Allen, Tobias Straub, Ignasi Forné, Andreas Ettinger, Stephan Hamperl, Axel Imhof and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Regulation of zygotic genome activation by the nucleocytoplasmic ratio.Frontiers in cell and developmental biology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meghana S Oak *Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany. meghana.oak@helmholtz-munich.de.ORCID http://orcid.org/0000-0001-5540-5660
Marco Stock *Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany.
Ana JanevaInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany.
Matthias MezesInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany.
Antony M Hynes-AllenDepartment of Clinical Neurosciences and MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Tobias StraubCore Facility Bioinformatics, Biomedical Center Munich (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Martinsried, Germany.ORCID http://orcid.org/0000-0002-0547-0453
Ignasi FornéProtein Analysis Unit, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Martinsried, Germany.
Andreas EttingerInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany.ORCID http://orcid.org/0000-0001-6436-010X
Stephan HamperlInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany.ORCID http://orcid.org/0000-0002-1658-7948
Axel ImhofProtein Analysis Unit, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Martinsried, Germany.
Jelle van den AmeeleDepartment of Clinical Neurosciences and MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2744-0810
Antonio ScialdoneInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany.
Eva HörmansederInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München, München, Germany. eva.hoermanseder@imp.ac.at.ORCID http://orcid.org/0000-0003-0340-6340

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 213249687Deutsche Forschungsgemeinschaft (German Research Foundation) HO 6864/2-1RCUK | Medical Research Council (MRC) MR/P00479/1Wellcome Trust
6 · The paper itself

Abstract

In vertebrate embryos, gene expression is first initiated at zygotic genome activation (ZGA). Maternally expressed transcription factors are essential for this process. However, it is unknown whether active chromatin modifications established in gametes are present in early embryos and contribute to ZGA and embryonic development. Here, we show that in Xenopus laevis, H3K4me3 occurs at common genomic loci in gametes, in transcriptionally quiescent pre-ZGA embryos, and in transcriptionally active ZGA embryos. These loci exhibit high H3K4me3 intensities and breadth, DNA hypomethylation, and elevated CpG content. We show that H3K4 methylation pre-marking is required for successful ZGA and development, including expression of the key ZGA transcription factor Pou5f3.2. We demonstrate that the H3K4 methyltransferase Cxxc1 ensures establishment of H3K4me3 and proper ZGA. These findings reveal a role for H3K4 methylation in defining active chromatin states in Xenopus laevis embryos and highlight its importance for accurate ZGA and embryonic development.

Indexed as

Gene Expression Regulation, DevelopmentalHistone CodeXenopus laevisZygoteAnimalsChromatinEmbryo, NonmammalianEpigenomicsGene SilencingHistone-Lysine N-MethyltransferaseMethylationTrans-ActivatorsTranscription FactorsTranscription, GeneticChromatinHistone-Lysine N-MethyltransferaseTrans-ActivatorsTranscription Factors

Identifiers

PMID41419741
PMCPMC12722762

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.